Clinical Research in Cardiology

, Volume 101, Issue 2, pp 149–153 | Cite as

A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation

  • D. Basic
  • H. Möllmann
  • M. A. Haas
  • A. Rolf
  • A. Jovanovic
  • Christoph Liebetrau
  • Sebastian Szardien
  • J. Leick
  • Oliver Dörr
  • A. Skwara
  • T. Walther
  • C. W. Hamm
  • H. M. Nef
Letter to the Editors
First Online:
Received:
Accepted:

Keywords

Mitral Regurgitation Left Ventricular Outflow Tract Myocardial Contrast Echocardiography Critical Illness Polyneuropathy Systolic Anterior Movement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer Iii WH, Spirito P, Ten Cate FJ (2003) American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy☆a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the european society of cardiology committee for practice guidelines. J Am Coll Cardiol 42(9):1687–1713. doi: 10.1016/s0735-1097(03)00941-0 PubMedCrossRefGoogle Scholar
  2. 2.
    Elliott P, McKenna W (2004) Hypertrophic cardiomyopathy. Lancet 363(9424):1881–1891. doi: 10.1016/s0140-6736(04)16358-7 PubMedCrossRefGoogle Scholar
  3. 3.
    Fifer MA, Vlahakes GJ (2008) Management of symptoms in hypertrophic cardiomyopathy. Circulation 117(3):429–439. doi: 10.1161/CIRCULATIONAHA.107.694158 PubMedCrossRefGoogle Scholar
  4. 4.
    Maron BJ (2007) Controversies in cardiovascular medicine: surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 116(2):196–206. doi: 10.1161/CIRCULATIONAHA.107.691378 (discussion 206)PubMedCrossRefGoogle Scholar
  5. 5.
    Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346(8969):211–214PubMedCrossRefGoogle Scholar
  6. 6.
    Rigopoulos AG, Seggewiss H (2010) A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 75(1):28–37PubMedCrossRefGoogle Scholar
  7. 7.
    Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, Seipel L, Horstkotte D (2005) Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German cardiac society. Z Kardiol 94(8):516–523. doi: 10.1007/s00392-005-0256-8 PubMedCrossRefGoogle Scholar
  8. 8.
    Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287(10):1308–1320PubMedCrossRefGoogle Scholar
  9. 9.
    Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55(8):823–834. doi: 10.1016/j.jacc.2009.09.047 PubMedCrossRefGoogle Scholar
  10. 10.
    Maron BJ (2000) Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 355(9202):425–426. doi: 10.1016/S0140-6736(00)82005-X PubMedCrossRefGoogle Scholar
  11. 11.
    Fifer MA (2007) Controversies in cardiovascular medicine: most fully informed patients choose septal ablation over septal myectomy. Circulation 116(2):207–216. doi: 10.1161/CIRCULATIONAHA.107.688135 (discussion 216)PubMedCrossRefGoogle Scholar
  12. 12.
    Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM (2003) Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 42(2):296–300PubMedCrossRefGoogle Scholar
  13. 13.
    Angelini P (2007) The “1st septal unit” in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience. Tex Heart Inst J 34(3):336–346PubMedGoogle Scholar
  14. 14.
    Aqel RA, Hage FG, Zohgbi GJ, Tabereaux PB, Lawson D, Heo J, Perry G, Epstein AE, Dell’ Italia LJ, Iskandrian AE (2008) Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients. Am J Cardiol 101(9):1328–1333. doi: 10.1016/j.amjcard.2007.12.042 PubMedCrossRefGoogle Scholar
  15. 15.
    Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA (2006) Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97(10):1511–1514. doi: 10.1016/j.amjcard.2005.12.040 PubMedCrossRefGoogle Scholar
  16. 16.
    Bartlett RH (2005) Extracorporeal life support: history and new directions. ASAIO J 51(5):487–489PubMedCrossRefGoogle Scholar
  17. 17.
    Robinson B, Eshaghpour E, Ewing S, Baumgart S (1998) Hypertrophic obstructive cardiomyopathy in an infant of a diabtic mother. ASAIO J 44:845–847PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • D. Basic
    • 1
  • H. Möllmann
    • 1
    • 3
  • M. A. Haas
    • 1
  • A. Rolf
    • 1
  • A. Jovanovic
    • 1
  • Christoph Liebetrau
    • 1
    • 3
  • Sebastian Szardien
    • 1
  • J. Leick
    • 1
  • Oliver Dörr
    • 3
  • A. Skwara
    • 2
  • T. Walther
    • 2
  • C. W. Hamm
    • 1
    • 3
  • H. M. Nef
    • 1
    • 3
  1. 1.Department of CardiologyKerckhoff Heart and Thorax CenterBad NauheimGermany
  2. 2.Department of Cardiac SurgeryKerckhoff Heart CenterBad NauheimGermany
  3. 3.Department of CardiologyUniversity of Giessen, Medical Clinic IGiessenGermany

Personalised recommendations